দেশ: মার্কিন যুক্তরাষ্ট্র
ভাষা: ইংরেজি
সূত্র: NLM (National Library of Medicine)
PENICILLAMINE (UNII: GNN1DV99GX) (PENICILLAMINE - UNII:GNN1DV99GX)
Actavis Pharma, Inc.
ORAL
PRESCRIPTION DRUG
Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require t
Penicillamine capsules USP, 250 mg are white to off white, hard gelatin capsules and imprinted with “A98 ” on the cap with black ink. They are supplied as follows: Bottles of 100 (NDC 0591-4171-01) Storage Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep container tightly closed. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Manufactured In India By: Watson Pharma Private Ltd. Verna, Salcette Goa 403 722 INDIA Manufactured For: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454 Rev. A 5/2018
Abbreviated New Drug Application
PENICILLAMINE- PENICILLAMINE CAPSULE ACTAVIS PHARMA, INC. ---------- PENICILLAMINE CAPSULES USP RX ONLY Physicians planning to use penicillamine should thoroughly familiarize themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity. DESCRIPTION Penicillamine, USP is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy (see INDICATIONS). It is 3-mercapto-D-valine. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured: [α] 25°= -62.5° ± 2° (c = 1, 1N NaOH), D calculated on a dried basis. The structural formula is: C H NO S M.W. 149.21 It reacts readily with formaldehyde or acetone to form a thiazolidine-carboxylic acid. Penicillamine capsules USP for oral administration contain 250 mg of penicillamine, USP. Each capsule contains the following inactive ingredients: magnesium stearate and mannitol. Each capsule shell contains: gelatin, sodium lauryl sulfate and titanium dioxide. The imprinting ink contains: black iron oxide, potassium hydroxide, propylene glycol and shellac. CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From _in vitro _studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that one gram of penicillamine should be followed by the excretion of about 200 milligrams of copper; however, the actual amount excreted is about one percent of this. Penicillamine also reduces e সম্পূর্ণ নথি পড়ুন